Combination drug delivery with actively-targeted PLGA nanoparticles to overcome multidrug resistance in breast cancer
Authors:
- Hayrettin TonbulHTHayrettin Tonbul
- Adem SahinASAdem Sahin
- Ece TavukcuogluETEce Tavukcuoglu
- Gunes EsendagliGEGunes Esendagli
- Yılmaz CapanYCYılmaz Capan
- 1 December 2019
- journal article
- research article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 54
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Development and Evaluation of Paclitaxel Nanoparticles Using a Quality-by-Design ApproachJournal of Pharmaceutical Sciences, 2013
- P-glycoprotein Inhibition for Optimal Drug DeliveryDrug Target Insights, 2013
- Influence of Surface Coating of PLGA Particles on the Internalization and Functions of Human Endothelial CellsBiomacromolecules, 2012
- Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomesInternational Journal of Pharmaceutics, 2011
- Inhibition of P-Glycoprotein-Mediated Paclitaxel Resistance by Reversibly Linked Quinine HomodimersMolecular Pharmacology, 2009
- Super pH-sensitive multifunctional polymeric micelle for tumor pHe specific TAT exposure and multidrug resistanceJournal of Controlled Release, 2008
- Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude miceJournal of Cancer Research and Clinical Oncology, 2007
- Targeted pharmaceutical nanocarriers for cancer therapy and imagingThe AAPS Journal, 2007
- Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreasEuropean Journal of Cancer, 2004
- Transferrin receptor is inversely correlated with estrogen receptor in breast cancerBreast Cancer Research and Treatment, 1986